Affimed N.V. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.18 |
Market Cap |
$181.67 M |
Shares Outstanding |
62.43 M |
Public Float |
47.61 M |
Address |
Technologiepark Heidelberg Baden Wuerttemberg 69120 Germany |
Employees | - |
Website | http://www.affimed.com |
Updated | 07/08/2019 |
Affimed NV is a clinical stage biopharmaceutical company, which engages in discovering and developing highly targeted cancer immunotherapies. The company has three proprietary platform technologies which includes: NK-cell TandAbs, T-cell TandAbs and Trispecific Abs. The company was founded in 2000 and is headquartered in Heidelberg, Germany. |